Pulmonx (NASDAQ:LUNG) Stock Crosses Above 50-Day Moving Average - What's Next?

Key Points

• Pulmonx shares surged 27.3% and crossed above their 50-day moving average, reaching $2.77 before last trading at $2.52 on heavy volume.
• Third-quarter results beat expectations: adjusted loss was $0.19 per share versus $0.26 expected, while revenue increased 6% year over year to $22.84 million. Management maintained its 2026 revenue forecast of $90 million to $92 million.
• Analyst sentiment remains positive, with Stifel raising its price target to $4.00 and Canaccord setting a $5.00 target; however, recent insider selling and ongoing losses remain potential concerns.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) shares passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $2.02 and traded as high as $2.77. Pulmonx shares last traded at $2.52, with a volume of 7,248,277 shares traded.

Key Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Quarterly results exceeded expectations. Pulmonx reported an adjusted loss of $0.19 per share, better than the consensus estimate of a $0.26 loss. Revenue rose 6% year over year to $22.84 million, surpassing expectations of $21.93 million. Pulmonx Q3 Results
• Positive Sentiment: Losses narrowed and operating efficiency improved. GAAP net loss declined to $8.4 million from $14.0 million a year earlier, while operating expenses fell 18% to $24.9 million. Gross margin remained strong at 76%, and U.S. revenue increased 7% to $14.9 million. Pulmonx Revenue and Financial Metrics
• Positive Sentiment: Analysts raised or reaffirmed their bullish views. Stifel Nicolaus raised its price target from $2.50 to $4.00 and assigned a “buy” rating, while Canaccord reiterated its buy rating. These actions provide additional support for the stock’s rally. Stifel Nicolaus Rating Canaccord Rating
• Positive Sentiment: Financial guidance was maintained. Pulmonx kept its 2026 revenue outlook at $90 million to $92 million and ended the quarter with $52.7 million in cash and equivalents, giving investors continued visibility and liquidity. Pulmonx Third-Quarter Results
• Neutral Sentiment: Management will participate in upcoming investor conferences, potentially providing additional visibility into commercial execution and the company’s outlook. Pulmonx Investor Conferences
• Negative Sentiment: Reported insider activity has been unfavorable, with executives recording sales and no purchases during the past six months. Recent institutional filings also showed several large funds reducing their positions, although these data points may not reflect current trading decisions.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LUNG. Canaccord Genuity Group set a $5.00 price target on Pulmonx in a research note on Wednesday. Stifel Nicolaus lifted their price objective on Pulmonx from $2.50 to $4.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Weiss Ratings raised Pulmonx from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 25th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.67.

Pulmonx Stock Up 27.3%

The company has a market capitalization of $108.23 million, a PE ratio of -2.17 and a beta of 0.33. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. The company's 50-day moving average is $2.02 and its 200 day moving average is $1.65.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. The business had revenue of $22.84 million for the quarter, compared to the consensus estimate of $21.93 million. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. As a group, analysts anticipate that Pulmonx Corporation will post -1.05 EPS for the current year.

Insider Activity

In related news, General Counsel David Lehman sold 14,334 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $32,394.84. Following the sale, the general counsel directly owned 361,827 shares of the company's stock, valued at $817,729.02. This trade represents a 3.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Glendon French, III sold 41,882 shares of Pulmonx stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $94,653.32. Following the completion of the sale, the chief executive officer owned 1,137,936 shares of the company's stock, valued at $2,571,735.36. This represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 78,340 shares of company stock valued at $177,048 over the last ninety days. 7.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pulmonx

A number of large investors have recently added to or reduced their stakes in LUNG. Primecap Management Co. CA purchased a new stake in Pulmonx during the 2nd quarter valued at $5,996,000. Bank of America Corp DE boosted its stake in shares of Pulmonx by 60.3% in the 1st quarter. Bank of America Corp DE now owns 1,166,826 shares of the company's stock worth $1,505,000 after buying an additional 439,027 shares during the last quarter. Almitas Capital LLC purchased a new position in shares of Pulmonx in the 2nd quarter worth $1,383,000. BlackRock Inc. purchased a new position in shares of Pulmonx in the 2nd quarter worth $1,147,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Pulmonx in the second quarter worth $1,060,067. Institutional investors own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation is a medical device company focused on developing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's technologies are designed to reduce hyperinflation in damaged portions of the lung and help improve breathing, exercise capacity and quality of life.

Pulmonx's primary product is the Zephyr Endobronchial Valve, a bronchoscopically implanted, one-way valve intended for certain patients with severe emphysema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.